title: Is surgery still the optimal treatment for stage I non-small cell lung cancer?
abstract: There is debate about what is the optimal treatment for operable stage I non-small cell lung cancer (NSCLC). Although surgery has been the standard of care for centuries, recent retrospective and prospective randomized studies indicated that stereotactic ablative radiotherapy (SABR) could be an option for this group of patients with similar survival and less toxicities. However, to change the standard of care, more studies are needed and participating ongoing larger randomized studies is the best approach to resolve this controversy.
authors.affiliation: 1 Hunter Holmes McGuire VA Medical Center, Virginia Commonwealth University, Richmond, VA 23224, USA ; 2 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Drew
authors.initials: D
authors.lastname: Moghanaki
authors.affiliation: 1 Hunter Holmes McGuire VA Medical Center, Virginia Commonwealth University, Richmond, VA 23224, USA ; 2 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Joe Y
authors.initials: JY
authors.lastname: Chang
keywords: Surgery; non-small cell lung cancer (NSCLC); stage I; stereotactic ablative radiotherapy (SABR); stereotactic body radiotherapy (SBRT)